✦ LIBER ✦
385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa™) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen
✍ Scribed by G. Curigliano; O. De Cobelli; M.T. Sandri; L. Zorzino; C. Noberasco; T. De Pas; E. Scardino; V. Formica; S. Manzoni; F. de Braud
- Book ID
- 118621567
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 292 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.